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Abstract
Background: Healthcare workers in many countries are recommended to receive influenza vaccine to protect themselves as
well as patients. A monovalent H1N1 vaccine became available in Hong Kong in December 2009 and around 10% of local
healthcare workers had received the vaccine by February 2010.
Methods: We conducted a cross-sectional study of the prevalence of antibody to pandemic (H1N1) 2009 among HCWs in
Hong Kong in February–March 2010 following the first pandemic wave and the pH1N1 vaccination campaign. In this study
we focus on the subset of healthcare workers who reported receipt of non-adjuvanted monovalent 2009 H1N1 vaccine
(Panenza, Sanofi Pasteur). Sera collected from HCWs were tested for antibody against the pH1N1 virus by hemagglutination
inhibition (HI) and viral neutralization (VN) assays.
Results: We enrolled 703 HCWs. Among 104 HCWs who reported receipt of pH1N1 vaccine, 54% (95% confidence interval
(CI): 44%–63%) had antibody titer $1:40 by HI and 42% (95% CI: 33%–52%) had antibody titer $1:40 by VN. The proportion
of HCWs with antibody titer $1:40 by HI and VN significantly decreased with age, and the proportion with antibody titer
$1:40 by VN was marginally significantly lower among HCWs who reported prior receipt of 2007–08 seasonal influenza
vaccine (odds ratio: 0.43; 95% CI: 0.19–1.00). After adjustment for age, the effect of prior seasonal vaccine receipt was not
statistically significant.
Conclusions: Our findings suggest that monovalent H1N1 vaccine may have had suboptimal immunogenicity in HCWs in
Hong Kong. Larger studies are required to confirm whether influenza vaccine maintains high efficacy and effectiveness in
HCWs.
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In 2009 the first influenza pandemic of the 21st Century was
associated with a novel influenza A(H1N1) virus that emerged in
North America and rapidly spread around the world [1]. In
Hong Kong, the first imported pH1N1 case arrived in Hong
Kong on April 30, 2009. Activity of pH1N1 peaked locally in
September and had subsided by November [2]. pH1N1 was a
notifiable condition throughout the first wave and 36,000
laboratory-confirmed cases were notified including 1,400 HCWs,
from a local population of 7 million including 150,000 HCWs [2–
4]. Vaccination is considered as the most effective preventive
measure and a series of studies found that one dose in adults and
two doses in children of monovalent pH1N1 vaccine were
sufficient to generate seroprotective levels of antibody against
pH1N1 [5–10]. The Hong Kong government purchased 3
million doses of the Panenza monovalent pH1N1 vaccine
manufactured by Sanofi Pasteur, which was the only pH1N1
vaccine formulation used in Hong Kong. Local health authorities
started to administer the vaccine to members of five target groups
including HCWs from December 21, 2009, and extended the
vaccination campaign to the general community in January 2010
[11].
We conducted a cross-sectional study of the seroprevalence of
pH1N1 antibody among HCWs in Hong Kong following the first
epidemic wave. In a separate study we investigated antibody
seroprevalence in HCWs who reported that they had not received
pH1N1 vaccine [4]. In this study we focus on HCWs who reported
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receipt of pH1N1 vaccine and investigate factors associated with
antibody seroprevalence following vaccination.
Methods
Study design
We recruited HCWs between February 11 and March 31, 2010
in 6 public hospitals comprising the Hong Kong West cluster of
the local Hospital Authority, with a total workforce of around
7,000 HCWs in one acute care teaching hospital and five non-
acute hospitals [4]. We established fixed study locations in each
hospital, and participants were invited to participate in our study
by open advertisement to all cluster employees. Some participants
were approached for recruitment during their regular health check
in the cluster staff clinic. HCWs were eligible to participate if they
were Hong Kong residents and had worked in the cluster for at
least one month. Subjects provided 3 ml of clotted blood, and
other information including subject characteristics, history of
exposure to influenza infection, and pandemic and seasonal
vaccination history was collected by trained research assistants on
a short questionnaire. The study protocol was approved by the
Institutional Review Board of the University of Hong Kong/
Hospital Authority Hong Kong West Cluster. Written informed
consent was obtained from all participants.
Laboratory methods
Serum samples were stored in a refrigerated container at 2–8uC
immediately after collection and delivered to the laboratory at the
end of each working day for storage at 270uC prior to testing.
Serum specimens were tested for antibody responses to A/
California/04/2009 (H1N1) by hemagglutination inhibition (HI)
and viral microneutralization (VN) assays using standard methods
as previously described [4,12,13]. The hemagglutination inhibition
(HI) test was carried out in 96 well microtitre plates using reagents
provided by World Health Organization (WHO) Collaborating
Centre for Reference and Research on Influenza Melbourne or
the WHO Collaborating Centre, Centres of Disease Control,
Atlanta, GA using standard methods as detailed in the WHO
reagent kit and elsewhere. The pandemic H1N1 HA antigen was
not included in the WHO reagent kit and was prepared by culture
of A/California/04/2009 (H1N1) virus in MDCK cells.
The conventional neutralization test for the A/California/04/
2009 was carried out in micro-titre plates using neutralization of
virus cytopathogenic effect (CPE) in Madin-Darby Canine Kidney
(MDCK) cells. Serial serum dilutions in quadruplicate were mixed
with 100 tissue culture infectious dose 50 (TCID50) for 2 hours
and added to MDCK cells. One hour after infection, serum-virus
mixtures were removed and serum free MEM with 2 ug/ml
trypsin was added to each well. The plates were incubated and
cytopathic effect was observed to determine the highest serum
dilution that neutralized $50% of the wells. A virus back titration
and positive and negative control sera were included in each assay.
Statistical analysis
We compared the differences in the proportion of HCWs with
pH1N1 antibody titer $1:40 both by HI and VN between groups
with chi-squared tests or Fisher’s exact test and used the phi
coefficient to compare results between the two assays. We
compared antibody seroprevalence over time in our study with
the date of administration of pH1N1 vaccines to HCWs in Hong
Kong [14,15]. We used Generalized Estimating Equation model
to estimate 95% confidence intervals for seroprevalence adjusting
for potential clustering within hospitals. Among HCWs who did
not report confirmed pH1N1 infection, we used univariable and
multivariable logistic regression to explore associations between
presence of pH1N1 antibody titer $1:40 by HI and VN versus the
following factors: sex, age, and seasonal vaccine history in the
previous three years. Factors with p-value of 0.2 or lower in
univariable analyses were included in the multivariable models.
Multiple imputation was used to allow for a small amount of
missing data on some background characteristics and make the
most use of all available data [16].
Results
We recruited 703 HCWs during the study period, and
seroprevalence data for the 599 HCWs who reported that they
had not received pH1N1 vaccine have been reported elsewhere
[4]. Among the 104 HCWs who reported receipt of pH1N1
vaccine and who are the focus of the following analyses, 56
(53.8%, 95% CI: 44.2%–63.2%) had antibody titer $1:40 by HI
and 44 (42.3%, 95% CI: 33.2%–52.0%) had antibody titer $1:40
by VN. The phi coefficient for the comparison of antibody titers
$1:40 by HI or VN was 0.75.
Around 10% of HCWs in Hong Kong had received pH1N1
vaccine by January 2010 (Figure 1). We found no evidence of an
increase or decrease in antibody seroprevalence over time in
participants, and most participants were recruited more than a
month after the vaccination campaign had halted (Figure 1).
Three HCWs (46/M, 20/F, 55/F) reported having had confirmed
pH1N1 infection by reverse transcription polymerase chain
reaction [3] in addition to receiving pH1N1 vaccine, and 2/3
had antibody titer $1:40 both by HI and VN while the other
subject had antibody titer ,1:40 by both assays.
Among the 101 HCWs without confirmed pH1N1 infection, the
proportion of HCWs with antibody titer$1:40 by VN significantly
decreased with older age (test for trend, p,0.001), and was
significantly lower among HCWs who reported receipt of 2007–08
seasonal influenza vaccine (Table 1). In the logistic regression
model, statistically significant differences remained by age while no
statistically significant differences remained by seasonal influenza
vaccine history (Table 2). There was also a statistically significant
difference in the proportion of HCWs with antibody titer$1:40 by
HI among age groups, but not by seasonal vaccine history (Table 1).
Discussion
Influenza vaccination is recommended as the primary preven-
tion measure against infection, and HCWs are often one of the
groups targeted to receive vaccine not only for their direct
protection but also to indirectly protect vulnerable patients against
nosocomial infection [17,18]. However seasonal influenza vaccine
uptake rates are low among HCWs in many countries [19–24],
and pH1N1 vaccine uptake was also low in Hong Kong following
intense media coverage of a series of adverse events potentially
associated with pH1N1 vaccine [11,14,15]. Mandatory influenza
vaccination policies for HCWs remain controversial [18,25–27].
Around 15% of HCWs in our study reported receipt of one dose of
pH1N1 vaccine, compared to overall vaccine coverage of around
10% of HCWs in Hong Kong. However, among HCWs who
reported receipt of pH1N1 vaccine, only 54% had antibody titers
at or above the 1:40 level by HI that is conventionally associated
with protection against infection [28]. Among 599 HCWs who did
not report receipt of pH1N1 vaccine, 12% had antibody titer
$1:40 by VN during the same time period [4], which was much
lower than those who reported receipt of the pH1N1 vaccine. In
two studies of non-adjuvanted monovalent inactivated pH1N1
vaccine from the same manufacturer, 93% and 98% of adults
achieved antibody titer $1:40 by HI within 21 days [29] and
H1N1 Antibody Seroprevalence in Vaccinated HCWs
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immunogenicity appeared similarly high for other non-adjuvanted
pH1N1 vaccines [5,6,8]. Thus the monovalent pH1N1 vaccine
appears to have had only moderate immunogenicity in HCWs in
Hong Kong. There are three potential explanations for our
findings. Firstly, our results may indicate truly poor immunoge-
nicity of the vaccine specifically in HCWs who have had more
repeated annual seasonal influenza vaccine compared with general
population; secondly, our results may reflect imperfect effective-
ness of influenza vaccine in field condition for all recipients of the
vaccine; thirdly, our observed results may be biased by delays from
vaccination to serum collection.
While only 42% of HCWs had antibody titers $1:40 by VN,
which is consistent with the findings of another study of 409
HCWs in Japan who were provided with one dose of pH1N1
vaccine, and just 38% achieved antibody titers$1:40 by HI within
21 days of vaccination [30], 90% of confirmed cases achieved this
titer within 3–4 weeks of infection using the same assay in the same
laboratory [31]. We previously estimated that around 10%–15%
of HCWs were infected through the first wave and cumulative
incidence of infection was higher in younger HCWs [4] although
the majority of infections were not confirmed by laboratory testing
[3]. Higher pH1N1 antibody seroprevalence in younger HCWs
who reported receipt of pH1N1 vaccine (Table 1) could be
associated with a greater risk of infection rather than better
immunogenicity [4,12]. In addition, reduced immunogenicity of
pH1N1 vaccine in older adults has been reported in some previous
studies [5,6,8,10]. The proportion of HCWs with antibody titer
$1:40 by VN was significantly lower among HCWs who reported
receipt of 2007–08 seasonal influenza vaccine (Table 1), while no
statistically significant differences remained by seasonal influenza
vaccine history after adjustment (Table 2). An early report of the
immunogenicity of the same pH1N1 vaccine used in Hong Kong
found that geometric mean titer rises between baseline and 21
days after vaccination were significantly reduced in adults who had
previously received seasonal influenza vaccines in one or more
years between 2004–05 and 2007–08, but the geometric mean
titer was not associated with receipt of seasonal vaccine in 2008–09
[10]. Lowered antibody response to pH1N1 vaccine was also
associated with prior receipt of 2009–10 seasonal vaccine among
pregnant women in Japan [32], among infants and children in
Australia [33] and among high school students in Korea [34]. Pre-
or co-vaccination with seasonal influenza vaccine was associated
with poorer immunogenicity of a pH1N1 vaccine in two
randomized trials [35,36], while pre- or co-vaccination with
Figure 1. Timing of local vaccination campaign versus serum collection in our study. (A) Among 104 healthcare workers who reported
receipt of pandemic (H1N1) 2009 vaccine, the proportion of healthcare workers with antibody titer $1:40 to pandemic (H1N1) 2009 by
hemagglutination inhibition (HI) or viral microneutralization (VN) by week of specimen collection with 95% confidence intervals; (B) the number of
pandemic (H1N1) 2009 vaccines administered to 150,000 healthcare workers in Hong Kong from December 2009 through April 2010 (source:
Department of Health, Hong Kong [14,15]).
doi:10.1371/journal.pone.0027169.g001
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Table 1. Characteristics of 101 healthcare workers who reported receipt of monovalent pandemic (H1N1) 2009 influenza vaccine
and did not report confirmed pH1N1 infection.
Characteristica No.
Proportion with antibody
titer $1:40 by HI (95% CI) p-valueb
Proportion with antibody
titer $1:40 by VN (95% CI) p-valueb
Age 19–24 years 10 100% (69%–100%) 90% (56%–100%)
25–34 years 16 56% (30%–80%) 50% (25%–75%)
35–44 years 25 52% (31%–72%) 44% (24%–65%)
45–54 years 32 44% (26%–62%) 31% (16%–50%)
55–64 years 18 44% (22%–69%) 0.02 22% (6.4%–48%) ,0.01
Female sex 75 52% (40%–64%) 39% (28%–51%)
Male sex 26 58% (37%–77%) 0.78 50% (30%–70%) 0.44
Suffered febrile influenza-like illnessc since July 2009
No 40 53% (36%–69%) 35% (21%–52%)
Yes 61 54% (41%–67%) 0.96 46% (33%–59%) 0.38
Receipt of 2009–10 seasonal influenza vaccine
No 31 61% (42%–78%) 52% (33%–70%)
Yes 69 51% (38%–63%) 0.66 38% (26%–50%) 0.28
Receipt of 2008–09 seasonal influenza vaccine
No 42 60% (43%–74%) 52% (36%–68%)
Yes 57 49% (36%–63%) 0.41 33% (21%–47%) 0.09
Receipt of 2007–08 seasonal influenza vaccine
No 38 61% (43%–76%) 53% (36%–69%)
Yes 59 48% (34%–61%) 0.29 32% (21%–46%) 0.07
aSome columns do not total 104 due to missing data.
bp-values for association calculated by chi-squared tests or Fisher’s exact tests.
cinfluenza like illness is defined as temperature $37.8uC plus cough or sore throat.
doi:10.1371/journal.pone.0027169.t001
Table 2. Univariable and multivariable analysis of the factors associated with antibody titer $1:40 to pandemic (H1N1) 2009 by
viral neutralization among 101 healthcare workers who reported receipt of pandemic (H1N1) 2009 vaccine.
Characteristica
Crude odds ratio of titer
$1:40 (95% CI) Model 1
b Model 2c Model 3d
Adjusted odds ratio of
titer $1:40 (95% CI)
Adjusted odds ratio
of titer $1:40 (95% CI)
Adjusted odds ratio of
titer $1:40 (95% CI)
Age, years
19–24 11.45 (1.25–104.60) 15.58 (1.63–149.34) 10.89 (1.16–102.07) 14.08 (1.39–142.27)
25–34 1.27 (0.36–4.48) 1.51 (0.41–5.53) 1.42 (0.39–5.14) 1.48 (0.41–5.40)
35–44 1.00 1.00 1.00 1.00
45–54 0.58 (0.20–1.72) 0.76 (0.24–2.38) 0.75 (0.24–2.37) 0.74 (0.23–2.34)
55–64 0.36 (0.09–1.42) 0.52 (0.13–2.17) 0.36 (0.08–1.67) 0.39 (0.08–1.82)
Did not receive seasonal




0.46 (0.20–1.04) 0.45 (0.18–1.11) 0.49 (0.13–1.84)
Did not receive seasonal




0.43 (0.19–1.00) 0.61 (0.24–1.55) 1.05 (0.27–4.07)
aMultiple imputation was used to adjust for a small amount of missing data on some characteristics.
bModel 1: adjusted for the variables of age group and vaccination history in 2008–09.
cModel 2: adjusted for the variables of age group and vaccination history in 2007–08.
dModel 3: adjusted for the variables that had p-value,0.2 in univariable analyses, i.e. age group, vaccination history in 2007–08, and vaccination history in 2008–09.
doi:10.1371/journal.pone.0027169.t002
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pH1N1 vaccine was not found to affect the immunogenicity of a
seasonal influenza vaccine [36]. In addition to the association
between seasonal vaccine and pandemic vaccine, significant
association within seasonal vaccines in various years was also
supported by some studies. Poorer immunogenicity in subjects with
history of prior seasonal influenza vaccine was also reported in
studies of a seasonal A(H3N2) vaccine in adults [37], an adjuvanted
pH1N1 vaccine in adults [38] and an adjuvanted influenza
A(H5N1) vaccine in children [39]. Repeat vaccination with the
same strains has also been associated with poorer immunogenicity
of seasonal influenza vaccines [40,41]. Biological explanations for
the phenomenon of reduced immunogenicity associated with
repeated influenza vaccinations remain unclear [30,32,36].
Another possible reason for lower antibody response is
imperfect effectiveness of vaccine in field condition for the general
population. Various controlled trials have shown good immuno-
genicity of the pH1N1 vaccine [5,6,8,29]. To be effective in the
field, however, a number of elements in vaccination programs
need to be implemented properly, including proper cold chain and
vaccine management, at all levels; careful logistics management;
and safe management of the waste created during the campaign.
Failure to properly implement these can reduce the level of
protection that is expected from a vaccination program. A sero-
epidemiological survey in UK showed that proportion with HI
titers $1:32 in the 1–4 years old age-band started to decline after
receipt of monovalent vaccine [42], although increases in
seroprevalence would be expected after vaccine was being
delivered from January 2010 onwards for all children. In Hong
Kong, influenza vaccines are distributed every year through the
Hospital Authority staff clinics and special vaccination clinics, and
the Hospital Authority has substantial experience in maintaining
the cold chain and properly administering the vaccine. A separate
study in Hong Kong found overall seroprotection rates determined
by conventional MN and HI assays in vaccine recipients were
44.8% and 35.1% respectively within 243 days of vaccination [43].
Although information was not provided on the average delays
between vaccination and serum collection in that study, those
results could also be consistent with somewhat poorer pH1N1
vaccine immunogenicity in the general population in Hong Kong.
Although we did not record time of receipt of pH1N1 vaccine in
participants in our study, the majority of HCWs in Hong Kong
had received pH1N1 vaccine before mid-January 2010, i.e. at least
one month before the start of our study (Figure 1). Antibody
response induced by pH1N1 vaccine should be detectable within
21 days of receipt [5,6,8,9], and there was no indication that the
proportion of HCWs with antibody titers $1:40 by HI or VN
changed over time (Figure 1). Seroprotection rates following
seasonal influenza vaccination do not tend to drop substantially
from their peak, within 3 months of vaccination [44,45]. Another
study found that geometric mean titers could remain above
seroprotective levels within 3 months of pH1N1 vaccination for
adults aged between 18 and 28 [46]. Therefore a delay or decline
in antibody response following receipt of pH1N1 vaccine is
unlikely to explain our findings.
It is important to note several limitations of our study in
addition to the relatively small sample size. First, we conducted a
cross-sectional seroprevalence study following the first pH1N1
wave, and we did not have baseline (pre-pandemic) data to enable
us to compare the pre-pandemic antibody titer with the post-
pandemic antibody titer among HCWs [4]. Second, the 104
participants in our study were a small convenience sample
covering HCWs in both acute and non-acute hospitals, while a
random larger sample would have been ideal albeit more difficult
to implement with a high response rate. Previous vaccination
history and exposure assessment was based on self-report and
recall bias may have influenced the results. HCWs who were more
concerned about their health status in the pandemic might have
been more willing to participate in our study than others, while
also having protected themselves better when caring for patients
and been more willing to receive influenza vaccines. Finally, we
recruited HCWs who were working in 6 public hospitals on Hong
Kong island and our results may not generalize to HCWs working
in other regions of Hong Kong or local private hospitals and
outpatient clinics.
Vaccination is the most effective way to protect HCWs and the
patients around them from influenza, but uptake of influenza
vaccines tends to be low in many countries including Hong Kong.
Our study indicated lower antibody response than expected
among HCWs after receipt of pH1N1 vaccine than antibody
results of other two clinical studies using the same pH1N1 vaccine
[29]. Further studies are recommended to confirm the immuno-
genicity of the monovalent pH1N1 vaccines used in 2009–10, and
to investigate whether influenza vaccine retains high efficacy and
effectiveness in HCWs, many of whom receive annual influenza
vaccination, compared to other healthy adults with less prior
vaccine experience.
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